US agency NIH scraps nearly 40 clinical trials in India

Unstable regulatory environment has led to sponsors moving trials to places like Malaysia and Canada

Vidya Krishnan, Jacob P. Koshy
Updated11 Jul 2013, 09:13 AM IST
Photo: Mint<br />
Photo: Mint(Mint)

New Delhi: In a serious setback to clinical research in India, the National Institutes of Health (NIH), a part of the US department of health and human services, has cancelled approximately 40 ongoing clinical trials in the country, according to two people familiar with the development who asked not to be identified. NIH is one of the largest funders of research across the world.

add_main_imageThe move comes as the health ministry, after the Supreme Court’s intervention, tightened regulatory norms for trials. The health ministry amended the Drugs and Cosmetics Act with new laws for regulation and ethical supervision of trials; compensation of trial subjects; and mandatory accreditation of all stakeholders—institutional review boards, research institutions, sponsors and contract research organizations.

According to industry experts, an unstable regulatory environment has resulted in sponsors moving trials to favourable destinations such as Malaysia and Canada in the past six months. NIH and the US embassy did not respond to queries emailed to them on 4 July.NextMAds

Besides NIH, leading medical centres in the country such as Tata Memorial Hospital in Mumbai have also been hit by the regulatory chaos.

“The Drugs Controller General of India made it mandatory to register ethics committees. While this is a welcome step, they took nearly three months to register our committee. During this time, we could not start any trials. Slow turnaround time and lack of clarity in regulation have seen sponsored research slow down drastically. Even academic research has suffered in the past three months,” said C.S. Pramesh, chief of cardiothoracic surgery at Tata Memorial.

One of the people familiar with the development said the $500 million (around 3,000 crore) industry is functioning at one-fifth of its capacity currently.

M.K. Bhan, a former secretary with the biotechnology department, said the current crisis in the sector is a consequence of the government’s “overreaction”.

“There were problems in the way some trials were conducted as well as issues in the way clinical trials are governed. What we’ve seen now is a bit of an overreaction as part of course correction. There will be balance soon,” he said.

Bhan added that there was a technical committee examining the new rules in place for the clinical trials industry and it would be a matter of time before these problems were dealt with. Bhan was part of a nationwide group of researchers who, earlier this year, successfully announced the success of advanced, phase-3 trials of an indigenous, rotavirus vaccine known as Rotavac.sixthMAds

Meanwhile, industry executives maintain that patients have suffered the most. “Given the fact that we have the world’s highest disease burden, the most impacted by an unstable regulatory environment are patients for many of whom clinical research provided early access to new therapies and is often the only viable treatment option,” said Anil Raghavan, managing director of Quintiles India, a a contract research organization.

According to documents submitted by the Drugs Controller General of India in the Supreme Court, between January 2005 and June 2012, India approved 475 clinical trials for “new chemical entities” not used as drugs elsewhere in the world. The documents said that 11,972 adverse effects, excluding deaths, were reported in the period, with 506 of these being directly attributable to the trials. They put deaths from trials at 2,644 over the last five years.

Catch all the Politics News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.MoreLess
First Published:11 Jul 2013, 09:13 AM IST
HomepoliticspolicyUS agency NIH scraps nearly 40 clinical trials in India

Most Active Stocks

Indian Oil Corporation

03:58 PM | 12 JUL 2024
-7.6 (-4.36%)

Tata Steel

03:58 PM | 12 JUL 2024
-0.3 (-0.18%)

Bharat Electronics

03:59 PM | 12 JUL 2024
-2.25 (-0.67%)


03:56 PM | 12 JUL 2024
25.7 (4.81%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

KPIT Technologies

03:57 PM | 12 JUL 2024
154.25 (9.02%)

Inox Wind

03:59 PM | 12 JUL 2024
13.85 (8.76%)

Zensar Technologies

03:29 PM | 12 JUL 2024
50.45 (7.03%)


03:29 PM | 12 JUL 2024
386.65 (6.95%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K

    Fuel Price

    • Petrol
    • Diesel
    New Delhi
    HomeMarketsPremiumInstant LoanMint Shorts